RecruitingPHASE1, PHASE2NCT04086485
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Studying Embryonal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Frank I Lin, M.D., MD PhD FACPNational Cancer Institute (NCI)
- Intervention
- Lu-177-DOTATATE(drug)
- Enrollment
- 56 target
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2022 – 2028
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04086485 on ClinicalTrials.govOther trials for Embryonal carcinoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT05168631Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine TumorsLatin American Cooperative Oncology Group
- RECRUITINGNCT02688894The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]Samsung Medical Center
- RECRUITINGPHASE1, PHASE2NCT02174549Dose-defining Study of Tirapazamine Combined With Embolization in Liver CancerTeclison Ltd.
- RECRUITINGNANCT01980264Harmonics-based in Vivo Optical Virtual BiopsyNational Taiwan University Hospital